Hatem Humam, Leifeld Jörg
Department of Urology in Borromäus Hospital Leer, Germany.
Urol Case Rep. 2019 Jun 26;26:100955. doi: 10.1016/j.eucr.2019.100955. eCollection 2019 Sep.
The early intravesical Instillation of mitomycin C (MMC) is accepted as safe adjuvant therapy after TURBT by non-muscle- invasive bladder cancer if there is no perforation. In our case we report a female patient undergoing resection of papillary recurrent tumor on the anterior bladder wall. In the early postoperative period had the patient no complaints regarding to Instillation of MMC. The clinical manifestation of the necrosis of the anterior bladder wall appeared after one week requiring a long extended unsuccessful conservative therapy in order to save the bladder. Finally we performed a radical cystectomy. This complication is reported by some authors in literature.
对于非肌层浸润性膀胱癌，若未发生穿孔，术后早期膀胱内灌注丝裂霉素C（MMC）被认为是经尿道膀胱肿瘤电切术（TURBT）后的安全辅助治疗方法。在我们的病例报告中，有一位女性患者接受了膀胱前壁乳头状复发肿瘤切除术。术后早期，患者对MMC灌注无任何不适主诉。一周后出现膀胱前壁坏死的临床表现，为挽救膀胱进行了长时间的保守治疗但未成功。最终我们实施了根治性膀胱切除术。文献中已有一些作者报道过这种并发症。
